FDA rejects Vanda’s jet lag drug following yearslong dispute and 'long-shot' review - Endpoints News

FDA rejects Vanda’s jet lag drug following yearslong dispute and 'long-shot' review – Endpoints News

January 12, 2026

FDA rejects Vanda’s jet lag drug following yearslong dispute and ‘long-shot’ review Endpoints NewsFDA rejects Vanda’s jet lag treatment application By Investing.com Investing.com CanadaVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder PR Newswire